Pitavastatin — a New Inhibitor of HMG-CoA Reductase: Features of Clinical Pharmacology and Prospects of Use in the Treatment of Cardiovascular Diseases

G.V. Dzyak, K.Yu. Yegorov, E.L. Kolesnik


The article deals with the problem of correction of dyslipidemia in patients with cardiovascular disease, the attention is paid to the use of a new drug of statins class, pitavastatin, in this group of patients. The data of the international trials on comparative effectiveness of pitavastatin are provided, its advantages and safety profile were shown.


cardiovascular diseases; hypercholesterolemia; dyslipidemia; pitavastatin


Динаміка стану здоров’я народу України та регіональні особливості. Аналітично-статистичний посібник / Манойленко Т.С., Кириченко А.Г., Ревенько І.Л.; За ред. В.М. Коваленка. — К.: ННЦ «Інститут кардіології імені акад. М.Д. Стражеска», 2012. — С. 53.

Kotseva K., Wood D., De B.G. EURROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries // Eur. J. Cardivasc. Prev. Rehabil. — 2009. — Vol. 16. — P. 121-137.

Waters D.D., Brotons C., Chiang C.W. et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals // Circulation. — 2009. — Vol. 120. — P. 28-34.

Weng T.C., Yang Y.H., Em S.J. et al. A systematic review and meta-analysis on the therapeutic equivalence of statins // J. Clin. Pharm. Ther. — 2010. — Vol. 35. — P. 139-151.

Masana L. Pitavastatin in cardiometabolic disease: therapeutic profile // Cardiovasc. Diabetol. — 2013. — Vol. 12 (Suppl. 1). — S2.

Mukhtar R.Y., Reid J., Reckless J.P. Pitavastatin // Int. J. Clin. Pract. — 2005. — Vol. 12. — P. 239-252.

Neuvonen P.J., Niemi M., Backman J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance // Clin. Pharmacol. Ther. — 2006. — Vol. 12. — P. 565-581.

Fujino H., Yamada I., Shimada S. et al. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-me­thyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans // Arzneimittelforschung. — 2002. — Vol. 12. — P. 745-753.

Catapano A.L. Pitavastatin — pharmacological profile from early phase studies // Atheroscler SuppI. — 2010. — Vol. 12. — P. 3-7.

Saito Y. Pitavastatin: an overview // Atheroscler. ­Suppl. — 2011. — Vol. 12. — P. 272-276.

Aoki T., Nishimura H., Nakagawa S. et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-me­thylglutaryl-coenzyme A reductase // Arzneimittelforschung. — 1997. — Vol. 12. — P. 904-909.

Morikawa S., Umetani M., Nakagawa S. et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells // J. Atheroscler. Thromb. — 2000. — Vol. 12. — P. 138-144.

Corsini A., Ceska R. Drug-drug interactions with statins: will pitavastatin overcome the statins’ Achilles’ heel? // Curr. Med. Res. Opin. — 2011. — Vol. 27(8). — P. 1551-1162.

Jung J.A., Noh Y.H., Jin S. et al. Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers // Clin. Ther. — 2012. — Vol. 34(4). — P. 958-965.

Inagaki Y., Hunt T., Arana B. et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers // J. Clin. Pharmacol. — 2011. — Vol. 51(9). — P. 1302-1309.

Stender S., Budinski D., Hounslow N. Pitavastatin de­monstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia // Eur. J. Prev. Cardiol. — 2013. — Vol. 20(1). — P. 29-39.

Stender S., Budinski D., Gosho M. et al. Pitavastatin shows greater lipid-lowering efficacy over 12 weeks than pravastatin in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia // Eur. J. Prev. Cardiol. — 2013. — Vol. 20(1). — P. 40-53.

Warrington S., Nagakawa S., Hounslow N. Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men // Clin. Drug Investig. — 2011. — Vol. 31(10). — P. 735-743.

Mao Y., Yu J.M., Zhan Y.Q. et al. Safety and efficacy of pitavastatin in patients with hypercholesterolemia: a multicenter study // Zhonghua Yi Xue Za Zhi. — 2012. — Vol. 92(14). —

P. 968-973.

Morgan R.E., Campbell S.E., Yu C.Y. et al. Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects // J. Cardiovasc. Pharmacol. — 2012. — Vol. 60(1). — P. 42-48.

Han K.H., Rha S.W., Kang H.J. et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage) // J. Clin. Lipidol. — 2012. — Vol. 6(4). — P. 340-351.

Yokote K., Bujo H., Hanaoka H. et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study) // Atherosclerosis. — 2008. — Vol. 201(2). — P. 345-352.

Sasaki J., Ikeda Y., Kuribayashi T. et al. A 52-week, randomized, open-label, parallel-group comparison of the tole­rability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance // Clin. Ther. — 2008. — Vol. 30. — P. 1089-1101.

Teramato T., Shimano H., Yokote K. et al. New evidence on pitavastatin: efficacy and safety in clinical studies // Expert Opin. Pharmacother. — 2010. — Vol. 11(5). — P. 817-828.

Teramato T., Urashima M., Shimano H. et al. A Large-Scale Survey on Cardio-Cerebrovascular Events During pitavastatin (LIVALO Tablet) Therapy in Japanese patients with Hypercholesterolemia — LIVALO Effectiveness and Safety Study Extension (LIVES Study Extension) // Jpn. Pharmacol. Ther. — 2011. — Vol. 39. — P. 789-803.

Kishida K., Funahashi T., Shimomura I. Importance of Assessing the Effect of Statins on the Function of High-Density Lipoproteins on Coronary Plaque // Cardiovascular & Haematological Disorders — Drug Targets. — 2012. — Vol. 12. — P. 28-34.

Mao Y., Yu J.M., Zhang F. et al. The effect of pitavastatin on blood glucose and its efficacy in diabetic patients with hypercholesterolemia // Zhonghua Nei Ke Za Zhi. — 2012. — Vol. 51(7). — P. 508-512.

Hiro T., Kimura T., Morimoto T. et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter rando­mized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study) // J. Am. Coll. Cardiol. — 2009. — Vol. 54. — P. 293-302.

Warita S., Kawasaki M., Tanaka R. et al. Effects of pitavastatin on cardiac structure and function and on prevention of atrial fibrillation in elderly hypertensive patients: a prospective study of 2-years’ follow-up // Circ. J. — 2012. — Vol. 76(12). — P. 2755-2762.

Оптимизация терапии статинами пациентов высокого и очень высокого сердечно-сосудистого риска // Cardio Соматика. — 2011. — № 4. — С. 8.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта